Extended-release Horizant fails to gain FDA approval

02/17/2010 | Reuters

The FDA issued a complete-response letter for extended-release Horizant, a treatment for moderate to severe restless legs syndrome from XenoPort and GlaxoSmithKline. The drugmakers said they will communicate with the FDA on the future of the drug, which was linked to pancreatic acinar cell tumors in rats during preclinical studies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC